Amati AIM VCT (AMAT) Competitors

Alliance Pharma (LON:APH) and Amati AIM VCT (LON:AMAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Does the media prefer APH or AMAT?

In the previous week, Alliance Pharma had 1 more articles in the media than Amati AIM VCT. MarketBeat recorded 1 mentions for Alliance Pharma and 0 mentions for Amati AIM VCT. Alliance Pharma's average media sentiment score of 0.29 beat Amati AIM VCT's score of 0.00 indicating that Alliance Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Alliance Pharma	Neutral
Amati AIM VCT	Neutral

Which has more risk and volatility, APH or AMAT?

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Amati AIM VCT has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Is APH or AMAT a better dividend stock?

Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.3%. Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 7.0%. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Amati AIM VCT pays out -68.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.

Is APH or AMAT more profitable?

Amati AIM VCT has a net margin of 190.46% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -14.97% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alliance Pharma	-18.34%	-15.24%	5.98%
Amati AIM VCT	190.46%	-14.97%	-4.56%

Does the MarketBeat Community believe in APH or AMAT?

Alliance Pharma received 186 more outperform votes than Amati AIM VCT when rated by MarketBeat users. However, 70.83% of users gave Amati AIM VCT an outperform vote while only 61.89% of users gave Alliance Pharma an outperform vote.

Company	Underperform	Outperform
Alliance Pharma	Outperform Votes 203 61.89%	Underperform Votes 125 38.11%
Amati AIM VCT	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%

Which has better earnings & valuation, APH or AMAT?

Amati AIM VCT has lower revenue, but higher earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alliance Pharma	£183.50M	1.79	-£33.65M	-£6.20	-9.80
Amati AIM VCT	-£5.65M	-18.46	-£10.76M	-£7.28	-9.76

Do insiders & institutionals hold more shares of APH or AMAT?

66.3% of Alliance Pharma shares are held by institutional investors. 12.0% of Alliance Pharma shares are held by insiders. Comparatively, 0.5% of Amati AIM VCT shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer APH or AMAT?

Alliance Pharma presently has a consensus price target of GBX 6,250, indicating a potential upside of 10,179.61%. Given Alliance Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alliance Pharma is more favorable than Amati AIM VCT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alliance Pharma	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amati AIM VCT	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Alliance Pharma beats Amati AIM VCT on 12 of the 19 factors compared between the two stocks.